Crucell Gains Funding to Develop Malaria Vaccine
Dutch biotechnology firm Crucell said it had received $3.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to support the development of its malaria vaccine. Crucell
Dutch biotechnology firm Crucell said it had received $3.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to support the development of its malaria vaccine. Crucell